QIPB in Hip Surgery

September 2, 2026 updated by: Zeynep Yılmaz, Istanbul Medeniyet University

The Effect of the Quadro-Iliac Nerve Block on Postoperative Pain in Hip Surgery

In this single-center retrospective study, patients who underwent hip surgery between May 2025 and November 2025, with American Society of Anesthesiology (ASA) physical status I-III, aged 18 years and older, were screened. Patients who did not undergo a block for postoperative analgesia and who used patient-controlled analgesia were included in the control group. Patients who underwent QIPB and used patient-controlled analgesia were included in the block group. Patients' postoperative tramadol consumption, pain scores assessed using the Numerical Rating Scale, and rescue analgesia requirements were recorded. The primary endpoint was total opioid consumption over 24 hours, and the secondary endpoints were postoperative pain scores and rescue analgesia requirements.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye), 34700
        • Goztepe Prof Dr Suleyman Yalci City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients (≥18 years) who underwent intertrochanteric femur fracture surgery or total hip arthroplasty under spinal or general anesthesia at our institution during the study period and whose medical records were retrospectively reviewed. Patients were classified according to whether they had received QIPB for postoperative analgesia as part of routine clinical care.

Description

Inclusion Criteria:

  • ASA score I-III
  • Underwent femoral intertrochanteric fracture or total hip replacement surgery

Exclusion Criteria:

  • neurological deficits
  • mental retardation
  • history of alcohol or substance use

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control Group
Block Group
Drug: Quadro iliac Plane Block
Effectiveness in postoperative pain in hip surgeries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid consumption
Time Frame: 24 hours postoperatively
Tramadol consumption in mg
24 hours postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric Rating Scale
Time Frame: base, 8., 6., and 24. hour postoperatively
0: no pain, 10: the worst pain
base, 8., 6., and 24. hour postoperatively
The Need for Rescue Analgesics
Time Frame: within 24 hours postoperatively
paracetamol/nonsteroidal antiinflamatory drugs in mg
within 24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul Medeniyet University

Investigators

  • Principal Investigator: Mesure G.N. Ozden, Ass Prof, Goztepe Prof Dr Suleyman Yalcın City Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2025

Primary Completion (Actual)

October 30, 2025

Study Completion (Actual)

November 30, 2025

Study Registration Dates

First Submitted

March 9, 2026

First Submitted That Met QC Criteria

April 14, 2026

First Posted (Actual)

April 20, 2026

Study Record Updates

Last Update Posted (Actual)

September 8, 2026

Last Update Submitted That Met QC Criteria

September 2, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2025/0245 (NHS Research & Development Approval)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe